This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Evelo (EVLO) Drops 59% on Flunking Psoriasis Drug Study
by Zacks Equity Research
Evelo's (EVLO) EDP2939 fails to achieve the primary endpoint in a mid-stage for treating moderate psoriasis. The company decides to cease clinical development on the candidate.
Biotech Stock Roundup: ALDX, EVLO Down on Setback, SRRK Offers Updates & More
by Ekta Bagri
Regulatory and pipeline updates from Aldeyra Therapeutics (ALDX) and Scholar Rock (SRRK) are in focus in the biotech sector.
What Makes Evelo Biosciences, Inc. (EVLO) a New Buy Stock
by Zacks Equity Research
Evelo Biosciences, Inc. (EVLO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Forget Bargain Hunting, Buy 4 Stocks With Rising P/E
by Sanghamitra Saha
Tap four stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include James River Group (JRVR), MakeMyTrip Limited (MMYT), Evelo Biosciences (EVLO) and The Kroger Co. (KR).
After Plunging -40.39% in 4 Weeks, Here's Why the Trend Might Reverse for Evelo Biosciences, Inc. (EVLO)
by Zacks Equity Research
Evelo Biosciences, Inc. (EVLO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Down -39.46% in 4 Weeks, Here's Why Evelo Biosciences, Inc. (EVLO) Looks Ripe for a Turnaround
by Zacks Equity Research
The heavy selling pressure might have exhausted for Evelo Biosciences, Inc. (EVLO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Why Evelo Biosciences (EVLO) Might Surprise This Earnings Season
by Zacks Equity Research
Evelo Biosciences (EVLO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
5 Drug/Biotech Stocks Set to Outpace Q4 Earnings Estimates
by Kinjel Shah
Let us take a look at some drug/biotech stocks, EVLO, GMDA, APLS, MRTX and ITOS, which are poised to beat on fourth-quarter earnings.
Allakos (ALLK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Allakos' (ALLK) Q4 earnings call, investor focus is likely to be on updates on the progress of the company's lead pipeline candidate, lirentelimab.
BridgeBio (BBIO) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On BridgeBio Pharma's (BBIO) Q4 earnings call, investor focus is likely to be on updates on the progress of the company's pipeline candidates.
Evelo Biosciences, Inc. (EVLO) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Evelo Biosciences, Inc. (EVLO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis (ZTS) is set to report earnings and revenue figures and provide updates on its pipeline when it releases fourth-quarter 2021 results.
Wall Street Analysts Believe Evelo Biosciences, Inc. (EVLO) Could Rally 164%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 164.5% upside potential for Evelo Biosciences, Inc. (EVLO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Ultragenyx (RARE) Begins Angelman Syndrome Study in Canada
by Zacks Equity Research
Ultragenyx (RARE) and GeneTx Biotherapeutics dose the first patient in a phase I/II study on GTX-102 for treating patients with Angelman syndrome in Canada.
Evelo (EVLO) Posts Positive Data from Phase II Psoriasis Study
by Zacks Equity Research
Evelo Biosciences (EVLO) reports encouraging data from a phase II study evaluating EDP1815 for the treatment of mild and moderate psoriasis. Shares up in pre-market trading.
Implied Volatility Surging for Evelo Biosciences (EVLO) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Evelo Biosciences (EVLO) stock based on the movements in the options market lately.
Are Options Traders Betting on a Big Move in Evelo (EVLO) Stock?
by Zacks Equity Research
Investors need to pay close attention to Evelo (EVLO) stock based on the movements in the options market lately.
Anavex (AVXL) to Report Q3 Earning: What's in the Cards?
by Zacks Equity Research
On Anavex's (AVXL) earnings call for the fiscal third quarter, investor focus will mainly be on the company's progress with its lead investigational candidate for Alzheimer's disease.
Evelo Biosciences (EVLO) Looks Good: Stock Adds 5.9% in Session
by Zacks Equity Research
Evelo Biosciences (EVLO) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Evelo Biosciences, Inc. (EVLO) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Evelo Biosciences, Inc. (EVLO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Evelo Biosciences Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Evelo Biosciences has been struggling lately, but the selling pressure may be coming to an end soon.